What does InMode's flat Q2 revenue mean for my practice's equipment costs?

Flat revenue ($95.6M in Q2 2026 vs. Q2 2025) signals margin pressure on InMode, which typically leads to aggressive rebates and financing offers to move inventory. This creates a buyer's market—practices should negotiate harder on lease renewals and equipment pricing before manufacturers lock in terms.

Is InMode losing market share to competitors?

Yes. InMode faces competition from Cutera, Lumenis, and emerging ultrasound platforms like Sofwave, with practices consolidating device portfolios rather than adding new units. The company's premium pricing is losing ground to lower-cost RF alternatives as the market matures.

Should I renew my InMode equipment lease now or wait?

Monitor renewal terms closely. Margin compression typically precedes tighter rebate structures, so negotiate aggressively now while manufacturers are incentivized to move units. Waiting risks facing worse terms once inventory pressure eases.

What's driving the RF microneedling market slowdown?

Market saturation and competitive intensity are compressing InMode's growth. Practices are consolidating equipment rather than expanding, and the installed base is mature with limited new unit placements, suggesting the RF category has peaked in adoption.

Which device manufacturers should I consider as InMode alternatives?

Cutera and Lumenis are direct RF competitors gaining share, while Sofwave represents an emerging ultrasound alternative. Evaluate lower-cost RF options and alternative modalities as practices shift away from premium-priced platforms during market consolidation.

Devices & Tech

InMode Q2 Flat Revenue, Margins Compress

Energy-device leader faces stagnation and pricing pressure as market matures and competition intensifies.

By Evan at Inside MedSpa · Aug 5, 2026

1-YEAR MOVE

INMD ▲1.0%

1-year price move by ticker
Ticker	Company	1-year change
INMD	InMode Ltd.	+1.0%

InMode reported Q2 2026 GAAP revenues of $95.6 million, flat compared to Q2 2025, with margin compression evident in the earnings. The company's RF microneedling and radiofrequency platforms, once growth engines, are facing market saturation and competitive pressure.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/inmode-q2-flat-revenue-margin-pressure/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

InMode Q2 Flat Revenue, Margins Compress

Share

Discussion

Leave a comment

By the time it's news, it's too late.